Champions Oncology, Inc. (FRA:2I3)

Germany flag Germany · Delayed Price · Currency is EUR
5.85
+0.65 (12.50%)
At close: Dec 19, 2025
22.90%
Market Cap85.56M
Revenue (ttm)50.65M
Net Income (ttm)2.16M
Shares Outn/a
EPS (ttm)0.15
PE Ratio39.62
Forward PE144.05
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open6.10
Previous Close5.20
Day's Range5.85 - 6.10
52-Week Range4.84 - 11.10
Betan/a
RSI56.50
Earnings DateDec 15, 2025

About Champions Oncology

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1985
Employees 213
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 2I3
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.